|
As
Avandia’s Market Share Plunges, GSK Clarifies Its Safety
In
more Avandia
fallout, an
Impact RX report showed that Avandia’s (rosiglitazone;
marketed as Avandia by GlaxoSmithKline [GSK]) share of the
market for newly prescribed oral anti-diabetics fell to around
zero from around 10% in the two days after a study in The
New England Journal of Medicine (NEJM) reported that people
taking the drug are at greater risk of having a heart attack. At
the same time, Takeda Pharmaceutical Co. Ltd.'s rival drug Actos'
(pioglitazone hydrochloride) share of the new prescription market
increased from 10–22%. (5/29) AP/Forbes.com
In the
meantime, GSK confirmed that a letter summarizing additional
Avandia cardiovascular safety data from several large-scale
clinical trials was published in The
Lancet. Written by GSK’s Chief Medical Officer Dr.
Ronald L. Krall, GSK says it provides the necessary context and
clarifies the safety record of Avandia. (5/30) GlaxoSmithKline
See also:
Sen. Charles
Grassley said the FDA’s own analysis of Avandia confirms the
heart risks reported in NEJM. (5/25) AP/BusinessWeek
President-elect
of the American Diabetes Association, John Buse, voiced concerns
about heart risks among Avandia users in a letter to the FDA back
in 2000. (5/24) Reuters
|
